AzTrials
AzTrials

Acute Respiratory Distress SyndromeNCT06692634

Effects of End-inspiratory Pause on Ventilation

A study testing mechanical ventilation setting in people with Acute Respiratory Distress Syndrome, run by Clinica las Condes, Chile at 2 sites in Chile.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study aims to evaluate the effect of reducing tidal volume and respiratory rate together with an end-inspiratory pause setting on ventilatory efficiency and the distribution of inspired gas within the lungs in ARDS patients. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Acute Respiratory Distress Syndrome
What is being tested?
mechanical ventilation setting
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
2 sitesChile
Study dates
20 Nov 2024to 20 Nov 2024
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients ≥18 years of age with moderate and severe ARDS and up to 5 days of mechanical ventilation. Patients must be subjected to deep sedation and neuromuscular paralysis.

Who cannot join

  • Patients with hemodynamic instability, acute heart failure, previous chronic respiratory disease, and variations in oesophageal temperature higher than 0.5 °C in the last 2 hours were excluded

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Martín Benites, MD contact

+56 9 59226347

benitesmartinh@gmail.com

Chile2 sites
  • Clínica Las Condes

    Santiago, Santiago Metropolitan, 13114

  • Martín Hernán Benites

    Santiago, Santiago Metropolitan, 7550000

Other trials in Chile

About this study

Official title: Effects of Low Tidal Volume and Respiratory Rate Together With the Use of End-inspiratory on Alveolar Ventilation in ARDS Patients

This study aims to evaluate the effect of reducing tidal volume and respiratory rate together with an end-inspiratory pause setting on ventilatory efficiency and the distribution of inspired gas within the lungs in ARDS patients. The study will use non-invasive monitoring of respiratory function with volumetric capnography and tomography by electrical impedance to evaluate the physiologic function. The expected results include a significant reduction of mechanical energy delivered by mechanical ventilation, improved ventilatory efficiency, and generate more homogenous ventilation with the end-inspiratory pause.

Read the detailed description

Reduction of tidal volume (VT) to 6 mL/kg normalized to predicted body weight (PBW) and driving pressure limitation up to 15 cmH20 are essential ventilatory strategies that positively impact clinical outcomes of acute respiratory distress syndrome (ARDS) patients. Recently, mechanical power has also been linked to ventilator-induced lung injury (VILI) and associated with mortality, mainly due to its dynamic-elastic effects. However, despite using these low VT strategies, it is possible to develop VILI in moderate to severe ARDS patients, especially when driving pressure exceeds established safety limits for lung protection. In these situations, a VT less than 6 mL/kg-PBW is recommended, but an increase in respiratory rates (RR) is required to counteract the side effects of secondary hypercapnia (PaCO2 levels greater than 45 mmHg). In turn, the RR needed to achieve this target is at least 25 breaths/min, even if a mild degree of hypercapnia is often accepted. Yet, mechanical ventilator programming with higher RR per minute may promote lung tissue inflammation and could be associated with adverse outcomes in ARDS.

Thus, in ARDS is challenging to establish a combined strategy of tidal volume (VT) and respiratory rate RR reduction since its utmost problem is an increase in the partial pressure of carbon dioxide (PaCO2) and impairment of ventilatory efficiency, the magnitude of which is linked to the disease severity. For this reason, some non-invasive strategies are available to attenuate hypercapnia and improve the lung's ability to CO2 clearance. Among them, it is worth highlighting the end-inspiratory pause (EIP). This strategy has shown its usefulness in increasing CO2 clearance by improving the mean time given to inspired gas for distribution and diffusive mixing within the lungs. Nevertheless, the role of EIP as part of a protective ventilation strategy that combines the VT and RR reductions is unknown.

Therefore, we hypothesize that adding an end-inspiratory pause (EIP) improves CO2 expiration and that such an effect allows a decrease in the VT and RR for more lung-protective purposes. Thus, the main objective of this study is to evaluate the effects of an EIP on Bohr´s dead space (VDBohr/VT) and PaCO2 when combined with a VT and the RR reduction in ARDS. The secondary aim is to evaluate ventilatory strategy on air distribution and homogeneity by electrical impedance tomography.

Patient selection Patients ≥18 years of age with mild, moderate, and severe ARDS up to 5 days of mechanical ventilation. Patients must be under deep sedation and neuromuscular paralysis. Patients with hemodynamic instability, acute heart failure, previous chronic respiratory disease, and variations in oesophageal temperature higher than 0.5 °C in the last 2 hours will be excluded.

Baseline mechanical ventilation settings Mechanical ventilation at baseline will be programmed in volume-controlled mode with a Servo-i (Maquet, Solna, Sweden) and the following parameters: a VT of 7 ml/kg-PBW, an RR adjusted to ensure an arterial pH greater than 7.30 and no intrinsic positive end-expiratory pressure (PEEP), an inspiratory insufflation time of 0.6 seconds, an inspiratory: expiratory (I: E) ratio of 1:2, and no EIP. End-expiratory transpulmonary pressure will be set at the beginning of the study by electrical impedance tomography. The PBW was calculated as follows: 50+ [0.91 *(height in cm-152.4)] for men and 45.5+ [0.91* (height in cm-152.4)] for women. Active humidification will be used in all participants, and compressible volume compensation was performed in each mechanical ventilator used before starting the protocol.

Respiratory mechanics Airway pressure, esophageal pressure, and gas flow will be measured continuously by a proximal pneumotachograph (MBMED, Buenos Aires, Argentina). Data will be downloaded on a second laptop after proper flow and pressure sensors calibration. Respiratory driving pressure will be determined as plateau pressure minus total PEEP (PEEPTOT = external PEEP + intrinsic PEEP) and respiratory system compliance as Crs = VT/Pplat-PEEPTOT.

Respiratory mechanics were calculated offline using specific software, elastic-dynamic power was calculated according to Costa et al study, and minute ventilation was indexed by PBW.

Volumetric capnography Expired CO2 will be measured by an infrared mainstream sensor (Capnostat 5®; USA) and integrated into a monitor (MBMed CO2 Module). Volumetric capnograms were reconstructed automatically using MATLAB® (Natick, MA, USA), which allows ventilation analysis in volumetric capnograms using a mathematical algorithm that adjusts the tidal volume to the exhaled CO2. The following parameters were recorded: the airway dead space fraction (VDaw/VT), VDBohr/VT, index of gas exchange (VDEnghoff/VT), CO2 elimination per breath (VTCO2,br), alveolar minute ventilation, the fraction of expired CO2 (FECO2), minute elimination of CO2 (VTCO2,br * RR), end-tidal CO2 and the mean alveolar partial pressure of CO2 (PACO2).

The capnogram at phase III (SIII) is normalized (SnIII) by the FECO2 of the corresponding expiratory cycle. SnIII allows a comparison of slopes from breaths with different CO2 excretion rates, which could be expected to occur during modifications in the setting of the VT or RR. Alveolar minute ventilation will be calculated using the formula: alveolar ventilation * RR indexed by PBW. Ventilatory efficiency is defined as the relationship between alveolar ventilation per minute and minute ventilation.

The flow sensor is automatically adjusted to values recorded with the Body Temperature \& Pressure Saturated (BTPS) conversion factor to determine the exhaled air volume.

Electrical impedance tomography

A 16-electrode belt will be placed in the mid-thoracic region, and continuous lung impedance will be assessed by electrical impedance tomography (EIT) (Dräger Medical Systems, USA). Offline analysis of EIT data will be performed, and the following parameters were calculated:

  • Lung inhomogeneity is determined by the global inhomogeneity index (GI), which quantifies the homogeneity of the tidal volume distribution through quantitative lung pixel impedance dispersion.
  • Regional ventilation distribution is assessed by the impedance ratio (IR), a parameter for determining the dependent and non-dependent regions' air distribution. An IR > 1 represents a ventral distribution predominance, while an IR < 1 represents mainly a dorsal distribution. Briefly, the ventral region corresponds to regions of interest 1 and 2, and the dorsal region corresponds to regions of interest 3 and 4.
  • Tidal variation of impedance (TVI) represents impedance change generated by inspired gas during a respiratory cycle.
  • End-expiratory lung impedance (EELI) corresponds to the impedance value at the end of expiration.

Protocol All patients will be lying in a semi-recumbent position at 40 degrees, and before starting the study, a period of stabilization of 60 minutes must be mandated. PEEP and insufflation time settings will be kept constant throughout the study. For safety reasons, we predefined that the protocol could be stopped at any time in the event of significant alterations in systemic hemodynamics and/or respiratory acidosis (pH ≤ 7.25 and PaCO2 ≥ 60 mmHg).

The following data were collected at inclusion: demographic variables (age, sex, height), Acute Physiology, and Chronic.

Sequential protocol steps

  • Step I: Tidal volume (VT) 7 ml/kg-PBW, with constant positive end-expiratory pressure (PEEP), respiratory rate (RR), and insufflation time (0.6 sec), without adding an end-inspiratory pause (EIP). inspiratory: expiratory (I: E) ratio of 1:2. 60 minutes long.
  • Step II: VT 5 ml/kg-PBW with constant PEEP, RR, and insufflation time (0.6 sec) without adding an end-inspiratory pause (EIP). I:E ratio of 1:2. 60 minutes long.
  • Step III: EIP will be configured to achieve an I:E ratio of 1:1, keeping constant the insufflation time at 0.6 sec and the VT at 5 ml/kg-PBW. PEEP and RR will not be changed from baseline conditions. 60 minutes long.
  • Step IV: The RR will be reduced by 20%, keeping constant the VT in 5 ml/kg-PBW. The insufflation time will be maintained at 0.6 sec, and the I:E ratio was equal to 1:1; consequently, the EIP will be prolonged again. 60 minutes long.

Volumetric capnography will be recorded, and an offline analysis will be performed using the mean value of the last 40 breaths. Gas exchange measurements were also performed at the end of each phase using a conventional blood gas analyzer (GEM® 4000, Instrumentation Laboratory, Lexington, USA). Hemodynamic variables and pulse oximetry will be continuously monitored (Multiparameter Spacelabs 91393). To identify the influence of cardiac output variations on CO2 dynamics, minimally invasive cardiac output monitoring will be installed (Edwards Lifesciences, USA). If needed, a norepinephrine infusion will be used to maintain the mean arterial pressure near 65 mmHg, and no bolus of fluid was administered during the protocol.

Statistical analysis The Shapiro-Wilk test will be performed to determine the distribution of continuous variables, which will be expressed as mean, standard deviation, or median and interquartile range as appropriate. Friedman´s nonparametric test, the Wilcoxon matched-pairs signed-rank test, and Dunn's post hoc comparisons will be performed to compare multiple variables.

A two-tailed p-value less than 0.05 was considered statistically significant.

Being tested
mechanical ventilation setting
Keywords
Ventilatory Failure, Hypercapnia, Alveolar Hypoventilation
Medical subject headings
Respiratory Distress Syndrome, Hypoventilation, Hypercapnia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • mechanical ventilation settingOther

    VT reduction, EIP setting, RR reduction, and a new EIP programing.

Study groups in NCT06692634
Study groupRoleWhat they receive
Group 1ExperimentalReduce tidal volume from 7 ml/kg to 5 ml/kg. Set end-inspiratory pause. respiratory rate reduction until 20% of the basal condition, together with a new increase in end-inspiratory pause.
Receives: Other: mechanical ventilation setting
Group 2ExperimentalReduce tidal volume from 7 ml/kg to 5 ml/kg. Set end-inspiratory pause. respiratory rate reduction until 20% of the basal condition, and after that, will be set a new increase in end-inspiratory pause.
Receives: Other: mechanical ventilation setting

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. dead space reduction by 10%

    End inspiratory pause generates a 10% reduction of arterial carbon dioxide.

    Measured: After 60 minutes of applied the EIP setting

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Nov 2024
  2. Study start20 Nov 2024 (estimated)
  3. Primary completion20 Nov 2024 (estimated)
  4. Study completion20 Nov 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Single group
Model description
Step I: VT 7 ml/kg-PBW, with constant PEEP, RR, and insufflation time (0.6 sec), without adding an EIP. I:E ratio 1:2. Step II: VT 5 ml/kg-PBW keeping the other mechanical ventilation settings constant. Step III: EIP will be configured to achieve an I:E ratio of 1:1, keeping the other mechanical ventilation settings constant. Step IV: Patients will be randomized into two groups in a 1:1 ratio. Group 1: 20% reduction in RR together with a new setting in EIP until reach I:E equal 1, without modifying the other mechanical ventilation settings. Group 2: 20% reduction in RR without modifying the other mechanical ventilation settings. A modification of the I:E ratio will be generated concerning step III. After 60 minutes, a new EIP setting will be made until reaching an I:E ratio equal to 1. All steps will have a 60-minute long. Both arms will have the same programming of the mechanical ventilator at the end of the study.
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06692634
Sponsor's protocol ID
O01102022
Status last verified
Nov 2024
First submitted
14 Nov 2024
Last updated
18 Nov 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: I must request authorization from the institutional ethics committee to provide the information. Should you need any further information, please do not hesitate to contact me. benitesmartinh@gmail.com

Publications

  • Devaquet J, Jonson B, Niklason L, Si Larbi AG, Uttman L, Aboab J, Brochard L. Effects of inspiratory pause on CO2 elimination and arterial PCO2 in acute lung injury. J Appl Physiol (1985). 2008 Dec;105(6):1944-9. doi: 10.1152/japplphysiol.90682.2008. Epub 2008 Sep 18.

    PubMed 18801962
  • Aguirre-Bermeo H, Moran I, Bottiroli M, Italiano S, Parrilla FJ, Plazolles E, Roche-Campo F, Mancebo J. End-inspiratory pause prolongation in acute respiratory distress syndrome patients: effects on gas exchange and mechanics. Ann Intensive Care. 2016 Dec;6(1):81. doi: 10.1186/s13613-016-0183-z. Epub 2016 Aug 24.

    PubMed 27558174
  • Uttman L, Jonson B. A prolonged postinspiratory pause enhances CO2 elimination by reducing airway dead space. Clin Physiol Funct Imaging. 2003 Sep;23(5):252-6. doi: 10.1046/j.1475-097x.2003.00498.x.

    PubMed 12950321
  • Aboab J, Niklason L, Uttman L, Brochard L, Jonson B. Dead space and CO(2) elimination related to pattern of inspiratory gas delivery in ARDS patients. Crit Care. 2012 Dec 12;16(2):R39. doi: 10.1186/cc11232.

    PubMed 22390777

Questions about this trial

What is this clinical trial studying?

A study testing mechanical ventilation setting in people with Acute Respiratory Distress Syndrome, run by Clinica las Condes, Chile at 2 sites in Chile.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 18 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Chile. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Martín Benites, MD (+56 9 59226347, benitesmartinh@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

dead space reduction by 10% (time frame: After 60 minutes of applied the EIP setting). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06692634, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in